In Q3 2025, Essa Pharma remained in a pre-revenue phase, reporting a net loss of $6.3 million driven by ongoing research and administrative expenses while maintaining a solid cash position to support development efforts.

ESSA Pharma Inc. reported a net loss of $6,374,787 for the three months ended March 31, 2025. The company's total operating expenses decreased to $7,381,677 from $10,493,489 in the same period last year, primarily due to the wind-down of clinical trials and cessation of preclinical work. Cash and cash equivalents stood at $86,308,345, and total assets were $115,415,420.

ESSA Pharma reported financial results for the fiscal first quarter ended December 31, 2024, while continuing to explore strategic options focused on maximizing shareholder value following the termination of clinical development of masofaniten.

ESSA Pharma announced the termination of its clinical development of masofaniten and is evaluating strategic options to maximize shareholder value. The company reported financial results for Q4 and the fiscal year ended September 30, 2024.

ESSA Pharma is progressing towards significant milestones, including the presentation of mature durability data from the Phase 1 dose escalation study and the enrollment of the Phase 2 dose expansion study evaluating masofaniten in combination with enzalutamide.

ESSA Pharma reported its financial results for the second quarter of fiscal year 2024, highlighting progress in masofaniten combination studies and ongoing clinical development programs. The company's cash runway is expected to fund operations beyond 2025.

ESSA Pharma reported its financial results for the first quarter of fiscal year 2024. The company is focused on advancing masofaniten in combination with antiandrogen agents and is pleased with the data reported from the Phase 1 dose escalation study. ESSA expects its cash position will provide sufficient runway to fund planned operations through data readouts and beyond 2025.

ESSA Pharma reported on the progress of masofaniten (EPI-7386), its novel N-terminal domain androgen receptor inhibitor, including Phase 1 dose escalation data showing tolerability and PSA reductions when combined with enzalutamide in mCRPC patients. The company is focused on executing the Phase 2 combination study of masofaniten and enzalutamide in mCRPC patients and investigating masofaniten in combination with other standard of care antiandrogens. They anticipate their cash runway will fund planned operations through 2025.

ESSA Pharma reported its financial results for the third quarter ended June 30, 2023. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.

ESSA Pharma reported its cash position is expected to be sufficient to fund current and planned operations through 2025. The company continued to enroll patients into its Phase 1 study of EPI-7386 in combination with Xtandi® (enzalutamide).

ESSA Pharma reported its financial results for the fiscal first quarter ended December 31, 2022. The company's cash position is expected to be sufficient to fund current and planned operations through 2025.

ESSA Pharma reported its financial results for the fiscal year ended September 30, 2022, highlighting the achievement of major milestones with Phase 1 data for EPI-7386 and a strong cash runway expected to fund operations through 2025.

ESSA Pharma reported their Q3 financial results, highlighting the advancement of their lead candidate, EPI-7386, into the dose expansion phase and the initiation of combination trials. The company's cash position is expected to be sufficient to fund operations through 2024.

ESSA Pharma reported its financial results for the fiscal second quarter ended March 31, 2022. The company's cash position is expected to be sufficient to fund current and planned operations through 2024.

ESSA Pharma reported having cash reserves and short-term investments of $74,500,856 as of December 31, 2020, reflecting the gross proceeds of the July 2020 financing of $48.9 million, less operating expenses in the intervening period.

ESSA Pharma reported its financial results for the fiscal year ended September 30, 2020. The company had cash reserves and short-term investments of $78,332,100 as of September 30, 2020, which includes $48.9 million raised in a public offering in July.